Phase I trial of concomitant hyperfractionated radiotherapy with docetaxel and cisplatin for locally advanced head and neck cancer

Cancer Journal

Volumn 12, Issue 1, 2006, Pages 63-68

  Allal, Abdelkarim S ^a   Zwahlen, Daniel ^a   Becker, Minerva ^a   Dulguerov, Pavel ^a   Mach, Nicolas ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Cisplatin; Docetaxel; Head and neck cancer; Radiotherapy

Indexed keywords

CISPLATIN; DOCETAXEL;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; BRONCHOASPIRATION; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INFUSION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHAGIA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOLLOW UP; HEAD CANCER; HEART ARRHYTHMIA; HUMAN; INFECTION; KIDNEY FAILURE; LEUKOPENIA; LUNG DISEASE; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; MYELITIS; NECK CANCER; NEUTROPENIA; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PHOTON THERAPY; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME; WEIGHT REDUCTION; XEROSTOMIA;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; DEGLUTITION DISORDERS; DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MUCOSITIS; NECK DISSECTION; NEOPLASM STAGING; TAXOIDS; TREATMENT OUTCOME;

EID: 33645872107     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/00130404-200601000-00011     Document Type: Article

References (20)

1. Munro AJ. An overview of randomised controlled trials of adjuvant chemotherapy in head and neck cancer. Br J Cancer 1995;71:83-91.
2. El-Sayed S, Nelson N. Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region. A meta analysis of prospective and randomized trials. J Clin Oncol 1996;14:838-847.
3. Pignon JP, Bourhis J, Domenge C et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACHNC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000;355:949-955.
4. Horiot JC, Bontemps P, van den Bogaert W et al. Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial. Radiother Oncol 1997;44:111-121.
5. Fu KK, Pajak TF, Trotti A et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000;48:7-16.
6. Horiot JC, Le Fur R, N'Guyen T et al. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother Oncol 1992;25:231-241.
7. Overgaard J, Khan AR. Selective enhancement of radiation response in a C3H mammary carcinoma by cisplatin. Cancer Treat Rep 1981;65:501-503.
8. Schaake-Koning C, van den Bogaert W, Dalesio O et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 1992;326:524-530.
9. Huguenin P, Beer KT, Allal A et al. Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. J Clin Oncol 2004;22:4613-4621.
10. Vokes EE, Stenson K, Rosen FR et al. Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer. J Clin Oncol 2003;21:320-326.
11. Mason KA, Kishi K, Hunter N et al. Effect of docetaxel on the therapeutic ratio of fractionated radiotherapy in vivo. Clin Cancer Res 1999;5:4191-4198.
12. Leonard CE, Chan DC, Chou TC et al. Paclitaxel enhances in vitro radiosensitivity of squamous carcinoma cell lines of the head and neck. Cancer Res 1996;56:5198-5204.
13. Tishler RB, Norris CM Jr, Colevas AD et al. A phase I/II trial of concurrent docetaxel and radiation after induction chemotherapy in patients with poor prognosis squamous cell carcinoma of the head and neck. Cancer 2002;95:1472-1481.
14. Schoffski P, Catimel G, Planting A et al. Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group. Ann Oncol 1999;10:119-122.
15. Brizel DM, Albers ME, Fisher SR et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998;338:798-1804.
16. Allal AS, Bieri S, Miralbell R et al. Combined concomitant boost radiotherapy and chemotherapy in stage III-IV head and neck carcinomas: a comparison of toxicity and treatment results with those observed after radiotherapy alone. Ann Oncol 1997;8:681-684.
17. Fujii M, Tsukuda M, Satake B et al; Japan Cooperative Head and Neck Oncology Group (JCHNOG). Phase I/II trial of weekly docetaxel and concomitant radiotherapy for squamous cell carcinoma of the head and neck. Int J Clin Oncol 2004;9:107-112.
18. Airoldi M, Cattel L, Cortesina G et al. Docetaxel, carboplatin and concomitant radiotherapy for unresectable squamous cell carcinoma of the head and neck: pharmacokinetic and clinical data of a phase I-II study. Am J Clin Oncol 2004;27:155-163.
19. Varveris H, Mazonakis M, Vlachaki M et al. A phase I trial of weekly docetaxel and cisplatinum combined to concurrent hyperfractionated radiotherapy for non-small cell lung cancer and squamous cell carcinoma of head and neck. Oncol Rep 2003;10:185-195.
20. Jeremic B, Shibamoto Y, Milicic B et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol 2000;18:1458-1464.